These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1504 related articles for article (PubMed ID: 24857062)
1. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062 [TBL] [Abstract][Full Text] [Related]
2. Precision cancer medicine: the future is now, only better. Tsimberidou AM; Eggermont AM; Schilsky RL Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061 [TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X; Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236 [TBL] [Abstract][Full Text] [Related]
4. Personalized Medicine: Genomics Trials in Oncology. Hayes DF; Schott AF Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667 [TBL] [Abstract][Full Text] [Related]
5. An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Do K; O'Sullivan Coyne G; Chen AP Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298 [TBL] [Abstract][Full Text] [Related]
6. Perspectives on research activity in the USA on Cancer Precision Medicine. Bando H; Takebe N Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706 [TBL] [Abstract][Full Text] [Related]
7. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. Alden RS; Mandrekar SJ; Oxnard GR Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304 [TBL] [Abstract][Full Text] [Related]
8. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084 [TBL] [Abstract][Full Text] [Related]
9. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Coyne GO; Takebe N; Chen AP Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823 [TBL] [Abstract][Full Text] [Related]
10. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Shea M; Costa DB; Rangachari D Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497 [TBL] [Abstract][Full Text] [Related]
11. Maurie Markman on the Groundbreaking TAPUR Trial. Markman M Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751 [No Abstract] [Full Text] [Related]
12. National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond. Chen AP; Eljanne M; Harris L; Malik S; Seibel NL Cancer J; 2019; 25(4):272-281. PubMed ID: 31335391 [TBL] [Abstract][Full Text] [Related]
13. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development. Bando H; Takebe N Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340 [TBL] [Abstract][Full Text] [Related]
14. Giving Up on Precision Oncology? Not So Fast! Warner JL Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309 [No Abstract] [Full Text] [Related]
15. Methodology of clinical trials in lung cancer. Menis J; Besse B; Lacombe D Chin Clin Oncol; 2015 Dec; 4(4):44. PubMed ID: 26730756 [TBL] [Abstract][Full Text] [Related]
16. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Janiaud P; Serghiou S; Ioannidis JPA Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165 [TBL] [Abstract][Full Text] [Related]
17. American Society of Clinical Oncology Developing First Clinical Trial. Brower V J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625 [No Abstract] [Full Text] [Related]
18. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256 [TBL] [Abstract][Full Text] [Related]
19. Next-Generation Sequencing in Oncology in the Era of Precision Medicine. Blumenthal GM; Mansfield E; Pazdur R JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172 [No Abstract] [Full Text] [Related]
20. Delivering on the promise of precision cancer medicine. Berger MF; Van Allen EM Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852 [No Abstract] [Full Text] [Related] [Next] [New Search]